Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Anlotinib||Clinical Study||Actionable||In a retrospective analysis, addition of Anlotinib (AL-3818) to chemotherapy resulted in a partial response (PR) in 27% (11/41) and stable disease (SD) in 51% (21/41) of patients with advanced non-small cell lung cancer, compared to PR in 15% (8/53) and SD in 36% (19/53) of patients treated with chemotherapy alone, disease control rate (78% vs 51%, p=0.007) and median progression-free survival (5.0 vs 3.5 months, p=0.002) were significantly improved (PMID: 32547218).||32547218|